Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
about
The Crossroads of Geriatric Cardiology and Cardio-OncologyTreating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewCardiac effects of anticancer therapy in the elderlyEvaluation and management of patients with heart disease and cancer: cardio-oncologyOptimal management of breast cancer in the elderly patient: current perspectivesPotential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer DrugsTreatment of soft tissue sarcoma: a focus on earlier stages.Heart failure following cancer treatment: characteristics, survival and mortality of a linked health data analysis.Metabolic syndrome in Mexican women survivors of breast cancer: a pilot study at a general hospital.Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patientsExternal validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer.Current targeted therapies in breast cancer: clinical applications in the elderly woman.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathySIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly.Reconsideration of key articles regarding medication-related problems in older adults from 2011.Doxorubicin Cardiotoxicity and Cardiac Function Improvement After Stem Cell Therapy Diagnosed by Strain Echocardiography.Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphismsSerum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity.Senior adult oncology.Lipid nature and their influence on opening of redox-active liposomes.Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly.Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.Evidence-based risk assessment and recommendations for physical activity clearance: Consensus Document 2011.Treatment of the elderly patient with diffuse large B cell lymphoma.Treatment of metastatic breast cancer in women aged 65 years and older.Triple-negative breast cancer in the older population.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.An update on adjuvant systemic therapy for elderly patients with early breast cancer.Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.Hodgkin's Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge.Effects of doxorubicin cancer therapy on autophagy and the ubiquitin-proteasome system in long-term cultured adult rat cardiomyocytes.Illuminating anthracycline cardiotoxicity: the renaissance of evidence-based onco-cardiology.Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 s
P2860
Q26778666-228069B6-3C4C-422F-B6EE-815173EFD8ABQ26785496-52E21BFC-35C9-42F4-8968-1992F10E524CQ26850736-9A75387C-9850-47EC-B9F6-A259DF235184Q26863244-C8AAB096-A0F5-450F-ACC4-A461BB5562CCQ26998273-6186CEB1-0696-4C00-98A9-74028EB7541BQ27690879-77F5014E-DE03-4928-9CB4-27914D3EF4D8Q28070311-D8D58ABD-C933-4764-A823-4A163E049C88Q30240235-43A7F177-02B6-41EF-B831-0E7279282054Q31120288-14DDF8CF-568C-4955-B1F6-3B8A5184DD21Q34745890-AC9B105F-BB8E-400E-96F2-422D159FE7BFQ35030104-F4248992-64BF-457B-92DF-F27E592D20F3Q35125211-82460B18-6148-4968-A434-30AF80DBD5BAQ35584741-89457BA2-9067-4218-98D8-05AC50845BE5Q35673260-F91B4080-917C-4895-AED4-C06A161C4BC9Q35716026-779BD129-F4F2-47FF-A5AB-DBEFC2FF26A1Q36043785-54491C9F-9BBA-4452-B60B-4F2C4BB87B68Q36650772-626A1E76-3961-466A-AD6A-F8C8B9EAB0BDQ36804526-F8DA64BC-13C9-43F2-97A6-42169DF38DE6Q36825438-3C27ECDA-5001-4290-B099-8B12B0EFAF52Q36851424-7EA08902-914A-4B02-83D9-8561E72327E8Q37186746-1AB597BC-84C0-4CBF-86EF-C212EB564D7AQ37570641-3BF74040-E0C6-4285-BB7C-4CC748DA205FQ37719598-02BDF498-FF30-4B3B-ACD3-27183EE764C3Q37908100-6B189106-FE0A-4F9A-B3ED-545CB06B8BDFQ37998553-A6F954BD-4F0C-47C7-A681-7A455ABD6B8FQ38023511-EFBB7E2C-9A43-4595-9C4F-64D933C397ADQ38046584-EF1A6752-E665-4BDF-9FBE-8CF521501273Q38110232-F61F55AA-AF89-44D6-AFED-2169C156D407Q38165751-D98F0AA9-7AF7-4712-9FA6-7693FE238396Q38190105-7F3D69DE-5B2E-4F35-8DE2-0AE771427757Q38368230-4D9017A5-ED01-4A2B-8FBF-6A079E7C4810Q38787215-E2F3BF6B-0A7B-48FB-9D2A-35F7E4841729Q38931502-0EBC1A51-546B-469D-BCBA-7F4CC6380E50Q39742304-0900242A-1F08-4574-A661-905C25D4DE25Q40980827-30E9DACC-E12F-4DBB-9FC2-D0EC1483CC34Q41928716-7E321A2E-1FB8-443D-A628-93B348DD628FQ42080818-00969E07-C54D-4E8A-B347-ACBDAA327984Q42216535-A2818EDC-746D-4FF6-AF0C-E6F0FF28512AQ45180255-006EA399-9A94-4182-AFED-1388F66BF275Q47892546-DB3696E1-7EC0-4E7E-9452-288F7D8ED86B
P2860
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
@en
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
@nl
type
label
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
@en
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
@nl
prefLabel
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
@en
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.
@nl
P2093
P2860
P50
P356
P1433
P1476
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
@en
P2093
C Bernard-Marty
E G C Brain
K Krzemieniecki
P2860
P304
P356
10.1093/ANNONC/MDQ609
P577
2010-10-18T00:00:00Z